Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M002547200 on June 28, 2000

J. Biol. Chem., Vol. 275, Issue 43, 33607-33613, October 27, 2000
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
275/43/33607    most recent
M002547200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, B.
Right arrow Articles by Cohen, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, B.
Right arrow Articles by Cohen, P.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Direct Functional Interactions between Insulin-like Growth Factor-binding Protein-3 and Retinoid X Receptor-alpha Regulate Transcriptional Signaling and Apoptosis*

Bingrong LiuDagger , Ho-Young Lee§, Stuart A. Weinzimer, David R. Powell||, John L. Clifford§, Jon M. Kurie§, and Pinchas CohenDagger **

From the Dagger  Department of Pediatrics, University of California, Los Angeles, California 90095-1752, the § University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, the  Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, Pennsylvania 19104, and the || Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030

Received for publication, March 26, 2000, and in revised form, June 26, 2000

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Insulin-like growth factor-binding protein (IGFBP)-3 regulates apoptosis in an IGF-independent fashion and has been shown to localize to nuclei. We cloned the nuclear receptor retinoid X receptor-alpha (RXR-alpha ) as an IGFBP-3 protein partner in a yeast two-hybrid screen. Multiple methodologies showed that IGFBP-3 and RXR-alpha bind each other within the nucleus. IGFBP-3-induced apoptosis was abolished in RXR-alpha -knockout cells. IGFBP-3 and RXR ligands were additive in inducing apoptosis in prostate cancer cells. IGFBP-3 enhanced RXR response element and inhibited RARE signaling. Thus, RXR-alpha -IGFBP-3 interaction leads to modulation of the transcriptional activity of RXR-alpha and is essential for mediating the effects of IGFBP-3 on apoptosis.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The insulin-like growth factor (IGF)1-binding proteins (IGFBPs) are a family of proteins that bind IGFs with high affinity and specificity. They modulate IGF action by inhibiting or potentiating IGF binding to the IGF receptor. There are six high-affinity IGFBPs, of which IGFBP-3 is the most abundant in serum (1). Circulating IGFBP-3 is derived mainly from hepatic Kupffer cells, primarily under regulation by growth hormone, but IGFBP-3 is also produced locally in many tissues, where it serves important paracrine and autocrine roles in modulating cellular growth (2). In cells, IGFBP-3 is potently regulated by a number of factors including p53 (3), transforming growth factor-beta (4), and hypoxia-induced factor-1 (5). IGFBP-3 has been shown to directly induce apoptosis in prostate cancer cells (6), breast cancer cells (7), and other cell types. In these instances, IGFBP-3 acts directly, independently of the IGF-IGF receptor system, by binding to its own receptor(s), the nature of which is currently being unraveled.

The ability of IGFBP-3 to bind other molecules in addition to the IGFs has been previously demonstrated. IGFBP-3 binds to ALS, which together with IGF forms a stable ternary complex in serum (8). IGFBP-3 can undergo post-translational modification by proteases and can form an intermediary complex with plasmin and related enzymes (9). IGFBP-3 is noted to have a heparin-binding domain in its mid-region and is known to interact with heparin-containing molecules in the extracellular matrix (10) and with fibrin (11). Several groups, including our own, have demonstrated specific binding of IGFBP-3 to other uncharacterized proteins in serum (12), cell lysates (13), and cellular membranes (6). It has also been proposed that IGFBP-3 may share a common receptor with transforming growth factor-beta (14). It is of yet unclear what role these interactions play in mediating IGFBP-3 direct actions on cells.

IGFBP-3 has been observed in the nucleus of certain cells and contains a nuclear localization sequence that may facilitate shuttling into nuclei (15-17). The role of nuclear IGFBP-3 is currently unknown, but the cellular effects of IGFBP-3 appear to involve modulation of gene transcription, and thus, interactions of IGFBP-3 with transcription factors have been hypothesized.

The retinoid X receptor-alpha (RXR-alpha ) serves a key role in the regulation of gene transcription mediated by a variety of factors (18). RXR-alpha is an obligatory co-factor for the retinoic acid receptors, RARs (19), the peroxisome proliferator activating receptors (20), the thyroid receptors (21), and the vitamin D receptors (22). RXR-alpha can form heterodimers with these nuclear transcription factors and signal through specific DNA response elements such as the RARE, peroxisome proliferator receptor element, thyroid receptor element, and vitamin D receptor elements (23), or form homodimers and signal through RXRE (24). The activity of these transcriptional dimers is further regulated by a variety of transcriptional co-activators and co-inhibitors that modulate gene transcription in various states (25).

We report here the identification of a novel partner for IGFBP-3 in the form of the nuclear receptor RXR-alpha , confirm the validity of RXR-alpha /IGFBP-3 binding through multiple independent in vitro methods, and demonstrate physiologically significant consequences of RXR-alpha /IGFBP-3 binding on transcriptional signaling and cellular apoptosis. This unexpected interaction between the IGF/BP growth factor cascade and nuclear receptors represents a novel paradigm shift in our understanding of these systems.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- Protigen (Mountain View, CA) provided recombinant human IGFBP-3 and the NLS mutant IGFBP-3. Amersham Pharmacia Biotech (Sweden) provided recombinant human IGF-I. Ligand (San Diego, CA) and SRI International (Menlo Park, CA) provided the RXR-specific ligands LG1069 and SR11235, respectively. These ligands bind the retinoid receptor X exclusively with maximal binding achieved at 1 µM (26). 125I-IGFBP-3 and anti-human IGFBP-3 antibodies, which were affinity purified on an IGFBP-3 column, were purchased from DSL (Webster, TX). Anti-human RXR-alpha antibodies, RAR antibodies, and HeLa nuclear extracts were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). IGFBP-3 blocking peptides were purchased from Genemed Synthesis (South San Francisco, CA). Retinoic acid, dimethyl sulfoxide, and Igepal CA-630 were purchased from Sigma. Tris (crystallized free base) was purchased from Fisher (Fair Lawn, NJ). SDS-polyacrylamide gel electrophoresis (PAGE) reagents, Tween, and fat-free milk were purchased from Bio-Rad. Yeast two-hybrid screening kits were purchased from CLONTECH (Palo Alto, CA). The HeLa cDNA library was purchased from Stratagene (La Jolla, CA).

Yeast Two-hybrid Screening-- The yeast strain Saccharomyces cerevisiae HF7c (MATa, ura3-52, his3-200, lys2-801, ade2-101, trp1-901, leu2-3, 112, gal4-542, gal80-538, LYS2::GAL1-HIS3, URA3::(GAL4 17-mers)3-CYC1-lacZ)) was purchased from CLONTECH. The fusion gene IGFBP-3/BD was constructed by splicing cDNA encoding the human IGFBP-3 gene into the plasmid pGBT9 directly 5' to and in-phase with the gene encoding the binding domain (BD) of the yeast transcriptional activator GAL4 (CLONTECH). A HeLa cDNA library with the activation domain (AD) of the GAL4 gene was purchased from Stratagene and screened by co-transforming yeast with both plasmids. Yeast colonies were made competent for transformations according to the manufacturer's instructions (CLONTECH Matchmaker protocol handbook). Positive co-transformants were selected by growth on histidine-deficient agar media and assayed for beta -galactosidase activity according to the manufacturer's instructions (CLONTECH Matchmaker protocol handbook). All results were reproducible in at least two independent assays. Genes encoding IGFBP-3-binding proteins identified through this method were isolated by plasmid recovery, amplified using polymerase chain reaction, sequenced using the GAL4 activation domain sequencing primer, and compared with known sequences in GeneBank using the MacVectorTM software program (Oxford Molecular Ltd., Williamstown, MA).

Yeast Mating Assays-- IGFBP-3/BD was co-transformed with the candidate gene/AD construct into yeast, using the protocol for the two-hybrid system. The transformants were streaked on the SD agar plates without Leu and Trp or His, and incubated for 3 days at 30 °C. Expression of the LacZ gene by the co-transformants was determined by assaying for beta -galactosidase activity, CLONTECH.

Ligand Blots-- Reverse Western ligand blots were used to assess the binding of IGFBP-3 to RXR-alpha . GST, GST-RXR-alpha , or IGF-I were carefully dot-blotted directly onto nitrocellulose (2 µl at a time) and allowed to dry completely. The nitrocellulose was buffered in Tris-buffered saline (TBS), 3% Igepal CA-630 for 30 min. The membranes were blocked for 3 h with TBS, 1% bovine serum albumin, and then incubated overnight with 125I-IGFBP-3 (106 cpm) in TBS, 0.1% Tween, 1% bovine serum albumin. In some experiments, the incubation was performed in the presence of peptides analogous to domains of the IGFBP-3 molecule. The peptides used included: 1) an N-terminal-domain 20-mer peptide, corresponding to amino acids 33-52 in the IGFBP-3 protein: TELVREPGCGCCLTCALREG. 2) A peptide corresponding the nuclear localization sequence (NLS) within the heparin-binding domain (HBD). This 18-mer peptide corresponded to amino acids 215-232 in the IGFBP-3 protein: KKGFYKKKQCRPSKGRKR. The nitrocellulose was washed four times with TBS, 0.1% Tween and TBS. Autoradiography and phosphorimaging visualized the resulting bands. Experiments were repeated three times. Values of densitometrically analyzed values are expressed as mean ± S.D.

Co-immunoprecipitation and Western Immunoblots-- HeLa nuclear extracts were immunoprecipitated with anti-RXR-alpha or anti-IGFBP-3 antibodies. Briefly, 250 µl of protein A-agarose were incubated overnight at 4 °C with 5 µl of anti-human IGFBP-3 antibodies or 5 µl of anti-RXR-alpha antibodies. 125 µl of each antibody-treated protein A-agarose were added to 10 µg of HeLa nuclear extract and incubated for 3 h at 4 °C with shaking. Immunoprecipitated proteins were pelleted by centrifugation and washed 3 times with 100 µl of SACI buffer. 200-µl sample buffer (×1) were added to each sample and vortexed vigorously. Samples were boiled and vortexed again to release protein-antibody complexes from the protein A-agarose. The protein A-agarose was then separated from the immunoprecipitated complexes by centrifugation. The supernatants were saved, and the immunoprecipated proteins were separated by nonreducing SDS-PAGE (8%) at constant voltage overnight, then transferred to nitrocellulose for 4 h at 170 mA. The nitrocellulose was immersed in blocking solution (5% non-fat milk/TBS) for 45 min, washed with TBS, 0.1% Tween, and incubated with primary anti-human RXR-alpha or anti-human IGFBP-3 antibody (1:4,000) for 2 h. After washing off any unbound antibodies, the nitrocellulose was incubated with a secondary antibody (1:10,000) for 1 h. The membrane was washed 4 times with TBS, 0.1% Tween and TBS. Bands were visualized using the peroxidase-linked enhanced chemiluminescence detection system (ECL, Amersham Pharmacia Biotech). Experiments were repeated three times.

Immunoprecipitation and Autoradiography-- 125I-IGFBP-3 was incubated with 10 µg of HeLa nuclear extracts for 3 h at room temperature, and then with 5 µl of IGFBP-3, RXR-alpha , or RAR antibodies overnight. Complexes were then immunoprecipitated with protein A-agarose as above. Samples were subjected to separation on 12.5% nonreducing SDS-PAGE gel and autoradiography. Experiments were repeated three times.

GST Pull-down Assays-- The GST-RXR fusion vector encoded the full-length RXR molecule and was the generous gift of Dr. D. J. Mangelsdorf and has been previously described (27). GST-RXR-alpha fusion protein was produced in Escherichia coli DH5alpha , transformed with a GST- RXR-alpha construct, which were lysed and loaded on glutathione -Sepharose 4B beads from Sigma. 10 µg of purified GST-RXR-alpha bound to beads were incubated with 5 µg of recombinant IGFBP-3 protein or IGFBP-3 mutants and then separated by centrifugation. The bound proteins were analyzed by nonreducing SDS-PAGE followed by Western blotting using anti-IGFBP-3 antibody. Experiments were repeated three times.

Gel Mobility Shift Assays-- [gamma -32P]ATP-labeled RXRE or RARE were incubated with HeLa nuclear extracts in 25 µl of binding buffer containing 10 mM Tris, pH 7.5, 50 mM KCl, 1 mM EDTA, 0.5 mM dithiothreitol, 0.2% Nonidet P-40, 20 µg of bovine serum albumin, 36 µg of salmon sperm DNA, and 10% glycerol at 25 °C for 20 min. Mixtures were incubated with or without IGFBP-3 or RXR-alpha antibodies for an additional 30 min. Incubations were carried out with or without unlabeled competitors as indicated. Protein-DNA complexes were separated from free probe on a 4.5% polyacrylamide gel in 1 × TGE at 12 V/cm for 3 h, and visualized by autoradiography. Experiments were repeated three times.

Tissue Culture-- COS-7 cells, F9 embryonal carcinoma cells from ATCC, and F9 RXR-alpha -/- cells (28) were routinely maintained in Dulbecco's modified Eagle's medium containing 10% fetal calf serum (Life Technologies, Inc.), 100 units of penicillin/ml, and 100 units of streptomycin/ml in a humidified environment with 5% CO2. PC-3 cells from ATCC were cultured in F12K medium (Life Technologies, Inc.) supplemented with 10% fetal bovine serum, 100 units of penicillin/streptomycin per ml in a humidified environment with 5% CO2. LAPC-4 cells (29) were cultured in Iscove's modified Dulbecco's medium containing 10% fetal bovine serum (Qumega), 1% L-glutamine, 1% R1181 (NEN Life Science Products Inc.).

Transient Transfection Analysis-- Cells grown in 24-well culture plates were transfected with the appropriate combination of expression plasmids using LipofectAMINE (Life Technologies, Inc.). The total amount of plasmid DNA was adjusted to 500 ng/plate. The transfection solution was removed after 6 h of transfection, and the cells were cultured for 24 h. Cells were then incubated with or without 1 µM retinoic acid or RXR ligand overnight. Cells were subjected to luciferase assays as described previously (30). Luciferase activities were expressed as the means and standard deviations of five identical wells. Luciferase reporter plasmid constructs contained either the DR1 RXRE (AGGTCA), or the DR5 RARE (AGTTCA) in a direct repeat separated by 5 nucleotides in the context of a thymidine kinase heterologous promoter, or a control plasmid containing the thymidine kinase promoter but no response element (TK-LUC) (31). The full-length IGFBP3 cDNA was constructed in the expression vector (pKG3226) and co-transfected when indicated. Experiments were repeated three times. Values are expressed as mean ± S.D.

Cell Viability Assays-- Cells were plated at a starting density of 250 cells/well in 96-well plates and treated with varying doses of IGFBP-3 for 3 days. Cell number was determined as follows: the fluorescent dye calcein AM (1 mM) was added to the medium for 30 min prior to termination of the assay. The plate was then read on a Biolumen 960 fluorescence plate reader (Molecular Dynamics, Inc.). The excitation and emission wavelengths are 485 and 530 nm, respectively, for calcein AM. The intensity of fluorescence of enzymatically cleaved calcein AM is a positive measure of cell number. Values are expressed as mean ± S.D.

Apoptosis Enzyme-linked Immunosorbent Assay Assays-- Photometric cell death detection enzyme-linked immunosorbent assay (Roche Molecular Biochemicals, Indianapolis, IN) was performed to quantitate the apoptotic index by detecting the histone-associated DNA fragments (mono- and oligonucleosomes) generated by the apoptotic cells. The assay is based on the quantitative sandwich-enzyme immunoassay principle using mouse monoclonal antibodies directed against DNA and histones, respectively, for the specific determination of these nucleosomes in the cytoplasmic fraction of cell lysates. In brief, an equal number of LAPC-4 cells were plated in 24-well culture plates (1 × 104/cm2) in serum-supplemented medium, and grown to confluency for 72 h. At that time the confluent cells were washed with PBS and treated with IGFBP-3, an RXR ligand, and a combination thereof. The cells were dissociated gently (PBS with 0.1 M EDTA) and pelleted along with the floating cells (mostly apoptotic cells) collected from the conditioned media. The cell pellets were used to prepare the cytosol fractions, which contained the smaller fragments of DNA. Equal volumes of these cytosolic fractions were incubated in anti-histone antibody-coated wells (96-well plates) and the histones of the DNA fragments were allowed to bind to the anti-histone antibodies. The peroxidase-labeled mouse monoclonal DNA antibodies were used to localize and detect the bound fragmented DNA using photometric detection with 2,2'-azino-di-(3-ethylbenzathiazoline sulfonate) as the substrate. Calcium ionophore-treated conditions were used as positive controls. SFM-treated conditions were used as negative controls. Each experimental condition was performed with four samples and was repeated three times. The reaction products in each 96-well plate were read using a Bio-Rad microplate reader (model 3550-UV). Averages of the values ± S.D. from double absorbance measurements of the samples were plotted.

Immunofluorescence Confocal Microscopy-- 1 × 104 LAPC-4 cells were plated on coverglass in serum containing media for 2 days. The cells were then incubated in serum-free media with or without an RXR ligand (10-6 M) for 24 h before staining for immunofluorescence. After three washes in PBS, fixation and permeabilization of the cells were performed with 1% paraformaldehyde in PBS for 15 min at room temperature and 0.2% Triton X-100 in PBS for 15 min on ice, and cells were washed twice with PBS. IGFBP-3 protein localization was detected using the DSL hIGFBP-3 goat polyclonal antibody (which was previously purified an IGFBP-3 column), diluted 1:200, followed by fluorescein anti-goat antibody from Vector (Burlingame, CA). RXR-alpha protein was detected using an RXR-alpha -specific rabbit polyclonal antibody, diluted 1:150, followed by Texas Red anti-rabbit IgG from Sigma. Specimens were incubated with primary antibodies in PBS for 1 h at room temperature, with secondary antibodies in PBS for 40 min at room temperature, and then incubated with Hoechst from Electron Microscopy Sciences (Ft. Washington, PA) for 2 min. Samples were analyzed using the Inverted Confocal Microscope (Leica, Inc., Germany), equipped by digital camera Himamatsu (Japan), and operated by QED-image software.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cloning of RXR-alpha as an IGFBP-3 Partner-- A yeast two-hybrid system was used to identify novel IGFBP-3 partners. We utilized the yeast strain Hf7c (which is unable to grow in histidine, leucine, or tryptophan-deficient media) with a histidine-selection marker and beta -galactosidase marker under control by the GAL1 promoter. We performed co-transformations with: 1) pGBT9 plasmid containing the fusion gene IGFBP-3/GAL4 BD and a histidine-selection marker plus; 2) pGAD424 plasmid containing a HeLa cell cDNA library/GAL4 AD fusion gene and a tryptophan-selection marker. Positive co-transformants were isolated by growth on tryptophan-, leucine-, and histidine-deficient media, and colonies with beta -galactosidase activity were harvested to recover library plasmids. Library fragments were amplified using PCR and sequenced. We isolated a 1200-base pair cDNA fragment encoding the C-terminal portion of the human RXR-alpha gene followed by the 3'-untranslated region of the human RXR-alpha cDNA. Yeast mating experiments confirmed the interaction between IGFBP-3 and RXR-alpha and co-transfected colonies disclosed potent beta -galactosidase activity, which was completely absent in single transformants or in co-transformations of either hybrid with an empty vector. The RXR clone was one of 5 positive clones that reproducibly bound IGFBP-3 in the yeast two-hybrid screen. It was cloned out in four separate experiments.

Verification and Characterization of IGFBP-3-RXR-alpha Binding-- In order to investigate the specificity of RXR-alpha binding to IGFBP-3, we performed GST pull-down experiments using RXR-alpha linked to GST and various forms of IGFBP-3 proteins. GST-RXR-alpha was able to "pull-down" various forms of natural and recombinant IGFBP-3. As shown in Fig. 1, GST-RXR-alpha bound recombinant IGFBP-3 as well as the NLS mutant IGFBP-3, which has 2 amino acids mutated in the NLS region of IGFBP-3 (Table I). However, the IGFBP-3-HBD-BP1 mutant, in which 11 of the 18 amino acids in the HBD domain have been substituted to simulate the homologous region in IGFBP-1, which does not contain a heparin-binding domain (Table I), displayed no binding capacity for RXR-alpha . This suggests that RXR-alpha binding is specific to a region of IGFBP-3, which is within the HBD domain, but does not involve the NLS domain, which is part of it. In separate experiments, GST-RXR-alpha bound recombinant IGFBP-3 of both the glycosylated (Chinese hamster ovary-derived as well as baculovirus-derived) and non-glycosylated (E. coli-derived) forms, and also pulled-down serum, cell lysate, and conditioned media IGFBP-3 (data not shown). Reconstitution experiments with IGFBP-3 and the Sepharose beads indicated that less than 5% of the IGFBP-3 binds to the beads without RXR-GST being present.


View larger version (21K):
[in this window]
[in a new window]
  		Fig. 1.   GST-RXR-alpha pulls down IGFBP-3. Recombinant E. coli-derived 29-kDa IGFBP-3 protein, E. coli-derived 29-kDa IGFBP-3 NLS mutant, and baculovirus-derived 35-kDa IGFBP-3-HBD-BP1 mutant incubated with or without GST-RXR-alpha fusion protein, which was loaded on glutathione-Sepharose 4B beads. Proteins were analyzed by Western immunoblotting using anti-IGFBP-3 antibodies. RXR-alpha bound the wild type and the NLS mutant, but not the HBD-BP-1 mutant.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Sequences of IGFBP-3 mutants
Mutated residues are shown in bold. Amino acids 215-232 are commonly referred to the heparin-binding domain of IGFBP-3 (HBD) and contain the NLS. The IGFBP-3-HBD-BP1 mutant was engineered to contain the homologous sequence from IGFBP-1. The NLS mutant does not accumulate in the nucleus of cells (data not shown). The HBD mutant does not bind heparin (data not shown).

Western ligand dot blot assays confirmed IGFBP-3 binding to RXR-alpha as shown in Fig. 2. Increasing amounts of GST, GST-RXR-alpha protein, and IGF-I were dot-blotted onto nitrocellulose membranes, then incubated with 125I-IGFBP-3 with or without peptides homologous to the N terminus of the IGFBP-3 protein, or the HBD domain of IGFBP-3. IGFBP-3 potently bound to both RXR-alpha and IGF-I to a similar degree as shown in the blot depicted in Fig. 2A and in the phosphorimaged quantification in Fig. 2B. GST alone demonstrated no binding to IGFBP-3 (data not shown). As shown in Fig. 2A, there was no appreciable binding of IGFBP-3 to either human or bovine albumin nor to insulin. The N terminus peptide of IGFBP-3 blocked IGF-I binding, but had no effect on RXR-alpha binding (Fig. 2B), whereas the HBD peptide blocked RXR-alpha binding, but had no effect on IGF-I binding to IGFBP-3 (Fig. 2B). This indicates that RXR-alpha binds near the HBD domain of IGFBP-3, while IGF-I binding involves the N-terminal domain. In additional blots (data not shown) insulin, human albumin, and bovine albumin were dot blotted and probed with radiolabeled IGFBP-3 and showed no binding, indicating that RXR-IGFBP-3 binding is specific.


View larger version (51K):
[in this window]
[in a new window]
  		Fig. 2.   IGFBP-3 binds RXR-alpha near the HBD domain. A, Western ligand dot blot of IGF-I, GST-RXR-alpha , insulin, and albumin. 50 and 100 µmol of each protein were blotted on membranes, incubated with 125I-IGFBP-3, and autoradiographed. B, quantitated PhosphorImager data from A and similar experiments on IGF-I and RXR-alpha , plotted as bar graphs. Data is plotted as percent of maximal binding signal in the presence or absence of a 20-mer peptide homologous to the N terminus of the IGFBP-3 protein, which blocked IGF-I binding or an 18-mer peptide homologous to the HBD domain of the IGFBP-3 protein, which blocked RXR-alpha binding. * denotes p < 0.01.

In order to further investigate the specificity of RXR-alpha binding to IGFBP-3 in vivo, we performed co-immunoprecipitation experiments. In Fig. 3A, we used anti-IGFBP-3 and anti-RXR-alpha antibodies to immunoprecipitate these proteins and any interacting molecules from HeLa nuclear extracts then precipitated the samples with protein A-agarose. After separating the proteins using SDS-PAGE, we immunoblotted the membranes with anti-human IGFBP-3 antibodies (left) and anti-human RXR-alpha antibodies (right). IGFBP-3 antibodies immunoprecipitated all of the IGFBP-3 in the nuclear extracts samples and 39 ± 11% of the RXR-alpha available in the nuclear extracts. RXR-alpha antibodies successfully precipitated all the RXR-alpha in nuclear extracts and more than 84 ± 17% of the IGFBP-3 in the nuclear extract samples.


View larger version (33K):
[in this window]
[in a new window]
  		Fig. 3.   Co-immunoprecipitation of IGFBP-3 and RXR-alpha . A, immunoprecipitation (IP) of HeLa nuclear extracts with affinity-purified anti-human IGFBP-3 or anti-RXR-alpha antibodies bound to protein A-agarose and subsequent nonreducing SDS-PAGE and immunoblotting (IB) with anti-human IGFBP-3 or anti-RXR-alpha antibodies demonstrates co-immunoprecipitation of IGFBP-3 (at 44 kDa) and RXR-alpha (at 50 kDa). B, 125I-IGFBP-3 was incubated with HeLa nuclear extracts, antibodies for IGFBP-3, RXR-alpha , and RAR were applied, then precipitated with protein A-agarose before separation on 12.5% SDS-PAGE. Both the IGFBP-3 antibody and the RXR-alpha antibody precipitated a complex of 125I-IGFBP-3 and RXR-alpha , whereas the RAR antibody did not.

In Fig. 3B, 125I-IGFBP-3 was incubated with HeLa nuclear extracts. Antibodies for IGFBP-3, RXR-alpha , or RAR were bound with protein A-agarose and then further incubated with the nuclear extract mixtures. After precipitation, proteins were separated on 12.5% SDS-PAGE and autoradiographed. Both the IGFBP-3 antibody and the RXR-alpha antibody precipitated a complex of 125I-IGFBP-3 and RXR-alpha , whereas an RAR antibody did not precipitate IGFBP-3. This indicates that the IGFBP-3 -RXR-alpha binding is specific and that IGFBP-3 only binds RXR homodimers in HeLa nuclear extracts but does not bind RXR-RAR heterodimers.

Cellular Co-localization of RXR-alpha and IGFBP-3-- Using fluorescence immunocytochemistry with antibodies for IGFBP-3 and RXR-alpha , confocal microscopy revealed that IGFBP-3 and RXR-alpha were present in both the cytoplasm and nucleus of LAPC-4 cells (Fig. 4) and PC-3 cells (data not shown). Moreover, IGFBP-3 and RXR-alpha co-localized to a high degree in both cellular compartments. Furthermore, after the cells were treated with the RXR ligand LG1069 for 24 h, cytoplasmic IGFBP-3 and RXR-alpha both translocated to the nucleus as shown in the lower panel of Fig. 4. Similar results were seen upon treatment with 9-cis-RA (data not shown).


View larger version (18K):
[in this window]
[in a new window]
  		Fig. 4.   Co-localization of RXR-alpha and IGFBP-3. RXR-alpha and IGFBP-3 were localized in LAPC-4 cells by immunofluorescent confocal microscopy using specific antibodies. IGFBP-3 and RXR-alpha were present and displayed a high degree of co-localization in the cytoplasm and nucleus of LAPC-4 cells in serum-free media (SFM). After the cells were treated with an RXR-specific ligand (LG1069) for 24 h, both proteins were more evident in the nucleus, suggesting a ligand-dependent co-transport.

Interactions of IGFBP-3 with the RXR-alpha ·RXRE Complex-- Fig. 5 demonstrates the interactions of IGFBP-3 with the DNA-transcription factor complex involving RXR-alpha and the RXR response element (RXRE) in electromobility shift assays. HeLa nuclear extracts were incubated with 32P-labeled DR-1 RXRE, then separated by 4.5% polyacrylamide gel. Specific binding of RXR-alpha in HeLa nuclear extracts to the DR-1 RXRE was demonstrated in lanes 1-3. As expected, the addition of an RXR-alpha antibody in lane 8 supershifts the complex. The addition of an IGFBP-3 antibody in lane 4 also supershifts the complex, indicating that IGFBP-3 is bound to the RXR·RXR-alpha complex. Similarly labeled DR-5 RARE binds RAR in HeLa nuclear extracts (lane 5), but this complex did not supershift with an IGFBP-3 antibody, suggesting that IGFBP-3 only forms a complex with the RXR-RXR homodimer, not with RXR-RAR heterodimers. Conducting these experiments in the presence of RXR-specific ligands had no effect on the ability of IGFBP-3 antibodies to supershift the complex, suggesting that RXR-alpha binds IGFBP-3 at a site different than the ligand-binding domain of the RXR-alpha molecule.


View larger version (84K):
[in this window]
[in a new window]
  		Fig. 5.   IGFBP-3 binds the RXR-RXRE transcription factor-DNA complex. HeLa nuclear extracts were incubated with 32P-labeled RXRE DR-1 (lanes 1-4 and 7-8) or RARE DR-5 (lanes 5-6) in electromobility shift assays then separated by 4.5% polyacrylamide gel. Binding of RXR-alpha in HeLa nuclear extracts to the DR-1 RXRE was demonstrated in lanes 2 and 7, and this binding was shown to be specific after it was abolished by excess unlabeled RXRE in lane 3. The addition of an RXR-alpha antibody in lane 8, supershifts the complex as does the addition of an IGFBP-3 antibody in lane 4. DR-5 RARE binds RAR in lane 5, but this complex did not supershift with an IGFBP-3 antibody in lane 6.

Effects of IGFBP-3 on RXR-alpha -mediated Signaling-- In luciferase-based transcriptional assays, we used the DR1-RXRE and the DR5-RARE reporter systems in COS7 (Fig. 6) and F9 cells (data not shown). In both cases, luciferase signaling was enhanced by co-treatment with the appropriate ligand (SR11235 or RA). However, IGFBP-3 co-transfections potently and dose-dependently inhibited RA signaling via RARE, but enhanced RXR-specific ligand signaling via the RXRE, indicating that IGFBP-3 enhances RXR-RXR homodimer-mediated signaling via the RXRE but blocks RAR-RXR heterodimer-mediated signaling via the RARE.


View larger version (17K):
[in this window]
[in a new window]
  		Fig. 6.   IGFBP-3 modulates RXR-alpha -mediated signaling. In luciferase-based transcriptional assays, we used the DR1-RXRE (A) and DR5-RARE (B) reporter systems in COS7 cells. Luciferase signaling was enhanced by co treatment with the RXR-specific ligand, SR11235 (A) or the RAR ligand retinoic acid (B). IGFBP-3 co-transfections potently and dose-dependently enhanced RXR-specific ligand signaling via the RXRE (A), but inhibited RA signaling via RARE (B). ** denotes p < 0.005.

Requirement of RXR-alpha for IGFBP-3 Actions-- To further study the functional interface of IGFBP-3 and RXR-alpha in the nucleus, we performed viability assays utilizing the F9 embryonic carcinoma cell line and a sister cell line, in which RXR-alpha has been knocked out (Fig. 7). IGFBP-3 treatment dramatically reduced cell viability in the F9 cell line, but IGFBP-3 had no discernible effects in the RXR-alpha knockout line, indicating that RXR-alpha is required for IGFBP-3 induced apoptosis. IGFBP-3 effects were seen to a similar extent in the range of 0.5-2.5 µg/ml, which is similar to the concentrations of IGFBP-3 found in biological fluids. This result is particularly dramatic, as we have previously published that N-4-hydroxyphenyl-retinamide can induce apoptosis of the RXR-alpha null cells in a manner equivalent to the WT cells (32).


View larger version (21K):
[in this window]
[in a new window]
  		Fig. 7.   RXR-alpha is required for IGFBP-3-induced apoptosis. Viability assays were performed utilizing the F9 embryonic carcinoma cell line and a sister cell line, in which RXR-alpha has been knocked out. IGFBP-3 treatment dramatic reduced cell viability in the F9 cell line, but IGFBP-3 had no discernible effects in the RXR-alpha -knockout line. * denotes p < 0.001.

Synergism between RXR-alpha and IGFBP-3-- Using apoptosis enzyme-linked immunosorbent assays as shown in Fig. 8, in the prostate cancer cell lines LAPC-4 (Fig. 8A) and LnCaP (Fig. 8B), treatment with IGFBP-3 (0.5 µg/ml) alone, or the addition of RXR-alpha agonist alone (1 µM) increased the level of apoptosis when separately added to cells. This is similar to published data (6, 33). However, in the presence of both IGFBP3 and the RXR specific ligand, there is an additive enhancement of apoptosis in both models, suggesting that the IGFBP-3 and RXR-alpha signaling pathways are connected.


View larger version (16K):
[in this window]
[in a new window]
  		Fig. 8.   RXR-alpha agonists and IGFBP-3 have additive effects on apoptosis. Using apoptosis enzyme-linked immunosorbent assays, in the prostate cancer cell lines LAPC-4 (A) and LnCaP (B), treatment with IGFBP-3 (0.5 µg/ml) alone, or the addition of the RXR-alpha agonist LG1069, alone (1 µM) increased the level of apoptosis, relative to serum-free (SF) media, when separately added to cells. However, in the presence of both IGFBP3 and the RXR specific ligand, there is an additive enhancement of apoptosis in both models. * denotes p < 0.05 relative to serum free. ** denotes p < 0.01 relative to either treatment alone.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In addition to its role as an IGF-carrying protein in serum, IGFBP-3 is recognized to modulate the interaction between IGFs and the type I IGF receptor (IGF-R). In this capacity, IGFBP-3 may be inhibitory to growth, by preventing IGF binding to the IGF-R, or growth-potentiating, by presenting IGFs to the IGF-R in a controlled fashion and preventing down-regulation of the IGF-R (34).

The discovery of IGF-independent modulation of cell growth and death by IGFBP-3 provided indirect evidence for the presence of specific IGFBP-3-binding proteins, which may be cell surface-associated, cytosolic, or nuclear in location. Evidence for specific IGFBP-3 receptors also comes from experiments characterizing IGFBP-3 as a growth-inhibitory factor in murine knockout cells lacking the IGF-R (35). Oh et al. (13) have demonstrated specific binding of IGFBP-3 to uncharacterized cell surface proteins of 20, 26, and 50 kDa in the estrogen receptor negative breast cancer cell line Hs578T by affinity cross-linking and immunoprecipitation. We have similarly identified proteins with IGFBP-3 binding ability in prostate whole cell lysates and plasma membranes (6). IGFBP-3 has also been demonstrated to bind a molecularly uncharacterized 400-kDa protein, which can also bind transforming growth factor-beta (37). Furthermore, the reports showing that IGFBP-3 is localized to the nucleus suggest that a nuclear receptor for IGFBP-3 may also exist or that IGFBP-3 may bind nuclear proteins and modulate their actions.

In this report, we describe for the first time the identification of RXR-alpha as an IGFBP-3-binding protein/receptor. After cloning RXR-alpha in a two-hybrid screen, we have demonstrated specific RXR-alpha to IGFBP-3 binding through several in vitro methods, including GST-pull down, co-immunoprecipitation, Western blot techniques, and confocal microscopy. These studies demonstrated not only that RXR-alpha associates with IGFBP-3 in nuclei, but that this binding occurs at a specific region of IGFBP-3, near the NLS/HBD domain.

We have further demonstrated physiologically significant ramifications of RXR-alpha /IGFBP-3 interactions on the modulation of cell proliferation and apoptosis in several mammalian cellular systems. RXR-alpha agonists and IGFBP-3 are both growth inhibitory in many cancer cells (38), and the co-incubation of these molecules in the LAPC-4 model resulted in an additive effect on apoptosis. This phenomenon is consistent with IGFBP-3 binding RXR dimers, and with the ability of IGFBP-3 to enhance RXRE-mediated signaling. This observation suggests that rexinoids may be more effective as anti-cancer agents in the presence of high IGFBP-3 levels. This is compatible with reports that show that high IGFBP-3 levels in serum protect from the risk of colon (39), breast (40), and prostate cancers (41).

The effects of IGFBP-3 on cell growth and apoptosis appear to require an intact RXR-signaling pathway, as RXR knockout cells were unresponsive to IGFBP-3-induced apoptosis. In mice, the targeted disruption of the RXR-alpha gene is embryonic lethal (42), however, cell-specific effects of RXR-alpha signaling has been unraveled with the use of the F9 cell system in which the essential role of RXR-alpha in mediating retinoid signaling has been established (43). The cell-regulatory effects of RXR-related transcriptional systems are very diverse. RXR-alpha is required for the actions of multiple natural ligands including thyroid hormone, vitamin D, and retinoic acid. RXR-alpha is also critical for the effects of several classes of novel drugs such as peroxisome proliferator activating receptor agonists, and synthetic retinoids, which are being developed as cancer therapies as well as agents for the treatment of diabetes and osteoporosis. The relationship between RXR-alpha and the IGF-IGFBP-3 axis is poorly understood. Retinoids enhance the expression of IGFBPs, including IGFBP-3, but rexinoids do not (44). Since we observed that IGFBP-3 blocks RA-mediated RAR signaling, this raises the possibility that a negative feedback loop which involves IGFBP-3 limits the extent of retinoid signaling through induction of IGFBP-3 which then blocks further RAR-mediated transcription. A further component of this loop may be related to the observation that IGF-I induces RAR-beta expression (36) (which would also be blocked by IGFBP-3).

The discovery of RXR-alpha as an IGFBP-3 interacting protein adds a further level of complexity to the modulation of cellular growth. In addition to the modulation of IGF activity at the cell membrane and direct interactions with its own specific receptors, IGFBP-3 may also affect cell growth through several RXR-alpha -dependent mechanisms. Namely, IGFBP-3 could enhance rexinoid action but block signaling mediated by ligands of other RXR-alpha partners. This represents a new paradigm in our understanding of the actions of peptide growth factors. As such, the IGFBP-3/RXR-alpha interaction represents an interface of two previously unrelated signaling pathways and opens new directions in studying cross-talk between growth factors and nuclear receptor ligands in cancer and other diseases.

    FOOTNOTES

* This work was supported in part by Grants 2R01 DK47591 and 1RO1 AI40203 from the National Institutes of Health and by awards from the Department of Defense, the American Cancer Society, and the Juvenile Diabetes Foundations (to P. C.). A preliminary account of this work was presented in part at the Annual Meeting of the Endocrine Society June 22, 1999, San Diego, CA.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

** To whom correspondence should be addressed: Professor and Director of Research and Training, Div. of Endocrinology, Dept. of Pediatrics, Mattel Children's Hospital at UCLA, 10833 Le Conte Ave., MDCC 22-315, Los Angeles, CA 90095-1752. Tel.: 310-206-5844; Fax: 310-206-5843; E-mail: hassy@mednet.ucla.edu.

Published, JBC Papers in Press, June 28, 2000, DOI 10.1074/jbc.M002547200

    ABBREVIATIONS

The abbreviations used are: IGFBP, insulin-like growth factor-binding protein; RXRalpha , retinoid X receptor alpha ; RA, retinoid acid; RAR, retinoid acid receptor; RARE, RAR response element; PAGE, polyacrylamide gel electrophoresis; BD, binding protein; AD, activation domain; GST, glutathione S-transferase; NLS, nuclear localization sequence; HBD, heparin-binding domain; TBS, Tris-buffered saline; PBS, phosphate-buffered saline; RXRE, retinoid X receptor response element.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Ferry, J. R., Cerri, R. W., and Cohen, P. (1999) Horm. Res. 51, 53-67
2. Jones, J. I., and Clemmons, D. R. (1995) Endocr. Rev. 16, 3-34
3. Buckbinder, L., Talbott, R., Velasco-Miguel, S., Takenaka, I., Faha, B., Seizinger, B. R., and Kley, N. (1995) Nature 377, 646-649
4. Oh, Y., Muller, H. L., Ng, L., and Rosenfeld, R. G. (1995) J. Biol. Chem. 270, 13589-13592
5. Feldser, D., Agani, F., Lyer, N. V., Pak, B., Ferreir, G., and Semenza, G. L. (1999) Cancer Res. 59, 3915-3918
6. Rajah, R., Valentinis, B., and Cohen, P. (1997) J. Biol. Chem. 272, 12181-12188
7. Gill, Z. P., Perks, C. M., Newcomb, P. V., and Holly, J. M. (1997) J. Biol. Chem. 272, 25602-25607
8. Janosi, J. B., Ramsland, P. A., Mott, M. R., Firth, S. M., Baxter, R. C., and Delhanty, P. J. (1999) J. Biol. Chem. 274, 23328-23332
9. Campbell, P. G., Durham, S. K., Suwanichkul, A., Hayes, J. D., and Powell, D. R. (1998) Am. J. Physiol. 27, E321-331
10. Firth, S. M., Ganeshprasad, U., and Baxter, R. C. (1998) J. Biol. Chem. 273, 2631-2638
11. Campbell, P. G., Durham, S. K., Hayes, J. D., Suwanichkul, A., and Powell, D. R. (1999) J. Biol. Chem. 274, 30215-30221
12. Collett-Solberg, P. F., Nunn, S. E., Beers-Gibson, T., and Cohen, P. (1998) J. Clin. Endocrinol. Metab. 83, 2843-2850
13. Oh, Y., Muller, H. L., Lamson, G., and Rosenfeld, R. G. (1993) J. Biol. Chem. 268, 14964-14971
14. Leal, S. M., Liu, Q., Huang, S. S., and Huang, J. S. (1997) J. Biol. Chem. 272, 20572-20576
15. Schedlich, L. J., Young, T. F., and Firth, S. M. (1998) J. Biol. Chem. 273, 18347-18352
16. Li, W., Fawcett, J., Widmer, H. R., Fielder, P. J., Rabkin, R., and Keller, G. A. (1997) Endocrinology 138, 1763-1766
17. Jaques, G., Noll, K., Wegmann, B., Witten, S., Kogan, E., Radulescu, R. T., and Havemann, K. (1997) Endocrinology 138, 1767-1770
18. Solomin, L., Johansson, C. B., Zetterstrom, R. H., Bissonnette, R. P., Heyman, R. A., Olson, L., Lendahl, U., Frisen, J., and Perlmann, T. (1998) Nature 395, 398-402
19. Boylan, J. F., Lohnes, D., Taneja, R., Chambon, P., and Gudas, L. J. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 9601-9605
20. Mukherjee, R., Davies, P. J., Crombie, D. L., Bischoff, E. D., Cesario, R. M., Jow, L., Hamann, L. G., Boehm, M. F., Mondon, C. E., Nadzan, A. M., Paterniti, J. R., Jr., and Heyman, R. A. (1997) Nature 386, 407-410
21. Collingwood, T. N., Butler, A., Tone, Y., Clifton-Bligh, R. J., Parker, M. G., and Chatterjee, V. K. (1997) J. Biol. Chem. 27, 13060-13065
22. Kliewer, S. A., Umesono, K., Mangelsdorf, D. J., and Evans, R. M. (1992) Nature 355, 446-449
23. Mangelsdorf, D. J., and Evans, R. M. (1995) Cell 83, 841-850
24. Lehmann, J. M., Jong, L., Fanjul, A., Cameron, J. F., Lu, X. P., Haefner, P., Dawson, M. I., and Pfahl, M. (1992) Science 258, 1944-1946
25. Westin, S., Kurokawa, R., Nolte, R. T., Wisely, G. B., McInerney, E. M., Rose, D. W., Milburn, M. V., Rosenfeld, M. G., and Glass, C. K. (1998) Nature 395, 199-202
26. Solomon, C., White, J. H., and Kremer, R. (1999) J. Clin. Invest. 103, 1729-1735
27. Janowski, B. A., Willy, P. J., Devi, T. R., Falck, J. R., and Mangelsdorf, D. J. (1996) Nature 383, 728-731
28. Clifford, J. L., Chiba, H., Sobieszczuk, D., Metzger, D., and Chambon, P. (1996) EMBO J. 15, 4142-4155
29. Craft, N., Shostak, Y., Carey, M., and Sawyers, C. L. (1999) Nat. Med. 5, 280-285
30. Glass, C. K., Lipkin, S. M., Devary, O. V., and Rosenfeld, M. G. (1989) Cell 59, 697-708
31. Lee, H. Y., Dohi, D. F., Kim, Y. H., Walsh, G. L., Consoli, U., Andreeff, M., Dawson, M. I., Hong, W. K., and Kurie, J. M. (1998) J. Clin. Invest. 101, 1012-1019
32. Clifford, J. L., Menter, D. G., Wang, M., Lotan, R., and Lippman, S. M. (1999) Cancer Res. 59, 14-18
33. de Vos, S., Dawson, M, I., Holden, S., Le, T., Wang, A., Cho, S. K., Chen, D. L., and Koeffler, H. P. (1997) Prostate 32, 115-122
34. Conover, C. A. (1992) Endocrinology 13, 3191-3199
35. Valentinis, B., Bhala, A., DeAngelis, T., Baserga, R., and Cohen, P. (1995) Mol. Endocrinol. 9, 361-367
36. Perez-Juste, G., and Aranda, A. (1999) Oncogene 18, 5393-5402
37. Leal, S. M., Huang, S. S., and Huang, J. S. (1999) J. Biol. Chem. 274, 6711-6717
38. Grimberg, A., and Cohen, P. (2000) J. Cell. Physiol. 18, 1-9
39. Ma, J., Pollak, M. N., Giovannucci, E., Chan, J. M., Tao, Y., Hennekens, C. H., and Stampfer, M. J. (1999) J. Natl. Cancer Inst. 91, 620-625
40. Hankinson, S. E., Willett, W. C., and Colditz, G. A. (1998) Lancet 351, 1393-1396
41. Chan, J. M., Stampfer, M. J., Giovannucci, E., Gann, P. H., Ma, J., Wilkinson, P., Hennekens, C. H., and Pollak, M. (1998) Science 279, 563-566
42. Wendling, O., Chambon, P., and Mark, M. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 547-551
43. Chiba, H., Clifford, J., Metzger, D., and Chambon, P. (1997) Mol. Cell. Biol. 17, 3013-3020
44. Hembree, J. R., Agarwal, C., Beard, R. L., Chandraratna, R. A., and Eckert, R. (1996) Cancer Res. 56, 1794-1799

Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Mol. Cell. Biol.Home page
L. Liao, X. Chen, S. Wang, A. F. Parlow, and J. Xu
Steroid Receptor Coactivator 3 Maintains Circulating Insulin-Like Growth Factor I (IGF-I) by Controlling IGF-Binding Protein 3 Expression
Mol. Cell. Biol., April 1, 2008; 28(7): 2460 - 2469.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
G. Zappala, C. Elbi, J. Edwards, J. Gorenstein, M. M. Rechler, and N. Bhattacharyya
Induction of Apoptosis in Human Prostate Cancer Cells by Insulin-Like Growth Factor Binding Protein-3 Does Not Require Binding to Retinoid X Receptor-{alpha}
Endocrinology, April 1, 2008; 149(4): 1802 - 1812.
[Abstract] [Full Text] [PDF]

Home page